<p>Age 18 &gt; years.</p> <p>Patient has a diagnosis of Atopic Dermatitis</p> <p>&gt; 10% Body surface</p> <p>Other conditions apply</p> <p>&nbsp;</p> <p>&nbsp;</p>

<ol> <li>Active malignancy, multiple myeloma, myeloproliferative or lymphoproliferative disorder, or a history of any of these conditions within 5 years prior to informed consent (except curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma or cutaneous squamous cell carcinoma)</li> <li>&nbsp;History of major immunologic reaction.</li> <li>Evidence of human immunodeficiency virus (HIV) infection.</li> <li>Positive for hepatitis C virus (HCV) antibody.</li> <li>Severe depression, poorly controlled schizophrenia.</li> <li>History of suicide attempts.</li> <li>Treatment with biological immunosuppressive or immunomodulatory therapy for AD or any other autoimmune, inflammatory, or allergic diseases&nbsp; ( eg. dupilumab, tralokinumab, lebrikizumab, other interleukin inhibitors, anti-immunoglobulin E [lgE], TNF inhibitors) Within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 pre-randomization.&nbsp;</li> <li>Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to day 1 pre-randomization.</li> </ol> <ul> <li>Systemic corticosteroids.</li> </ul> <p>Systemic treatment with methotrexate mycophenolate, calcineurin inhibitors, thalidomide, or other systemic immunosuppressants.</p> <p><strong>Others Exclusions</strong></p> <p>Female patients of childbearing potential are unwilling to use the protocol-specified method of contraception.</p> <p>&nbsp;</p>